The VT was frequently preceded by a variable period of bigeminal rhythm due to one or two premature ventricular beats coupled to the prolonged QT segment of the preceding basic beat ( Figure 1A and C). This 'short-long cardiac sequence' is seen in both acquired and congenital LQTS, and the arrhythmogenic mechanism may be related to increased dispersion of repolarisation (DR).
with an average length of 16 ± 8 beats. 2 The cycle length (CL) of these episodes ranged from 193 to 364 ms, with an average of 279 ± 47 ms.
The VT was frequently preceded by a variable period of bigeminal rhythm due to one or two premature ventricular beats coupled to the prolonged QT segment of the preceding basic beat ( Figure 1A and C). This 'short-long cardiac sequence' is seen in both acquired and congenital LQTS, and the arrhythmogenic mechanism may be related to increased dispersion of repolarisation (DR). 6 Following termination of an episode of fast VT, it is not uncommon to see one or more ectopic beats of variable configuration occurring at much longer CL compared to that of the VT (see beats marked by arrowheads in Figure 2 ). The change in QRS configuration during VT can take several forms. During a very fast VT, periodic decrease in the amplitude of the entire QRS-T complex is seen with less distinct shifts in QRS axis ( Figure   1A ). In VTs with slower rates, the classic twisting of the QRS axis from a predominantly positive to a predominantly negative configuration with a variable number of transitional complexes and vice versa is commonly seen as originally described by Dessertenne ( Figure 1B) . 7 Sometimes, a polymorphic QRS configuration is seen without any of the two previously characteristic patterns (as verified in multiple simultaneous leads, Figure   2C , middle recording). Different patterns can be seen in different VT episodes from the same patient ( Figure 1C ).
QT/T Wave Alternans and Torsade de Pointes
It has long been known that tachycardia-dependent T wave alternans (TWA) occurs in patients with the congenital or acquired form of LQTS and may presage the onset of TdP ( Figure 2 ).
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In an analysis of 1,103 LQTS patients with QTc interval >0.44 seconds from the International LQTS Registry, TWA was recorded in 30 patients. 8 The frequency of occurrence of TWA was directly proportional to the length of the QTc interval on the enrolment ECG. TWA occurred in one or more occasions during an average 4-year follow up in 21% of patients with QTc >0.60 seconds, but in <0.2% of patients with QTc <0.50 seconds. Patients with advanced forms of TWA (those with bidirectional beat-to beat changes in T wave polarity; n=21) were younger, had longer QTc values, had a higher incidence of complex VT, and were more likely to experience a cardiac event (syncope or cardiac arrest) than those with less advanced forms of TWA (those without bidirectional beat-to-beat changes in T wave polarity; n=9).
In contrast to TWA in congenital LQTS, the incidence of TWA in acquired LQTS is unknown. It has been reported in acquired LQTS due to hypokalaemia and hypomagnesemia ( Figure 3 ) 4 as well as in association with medications that prolong the QT interval ( Figure 3 ). 9 Patients with acquired LQTS and TWA are likely to develop TdP (Figures
and 3).
Although overt TWA in the ECG is not common, in recent years, digital signal processing techniques have made it possible to detect subtle degrees of TWA. 10 This suggests that the phenomenon may be more prevalent than previously recognised and may represent an important marker of vulnerability to VT. A recent report confirms this view,
showing that microvolt TWA is far more prevalent in LQTS patients than previously reported and is strongly associated with TdP history.
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Interest in TWA is attributed to the hypothesis that it reflects a greater degree of underlying DR.
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Aetiology of Acquired Long QT Syndrome
The vast majority of acquired LQTS is the result of adverse effects of drugs that interact with the hERG gene, and the I Kr . However, although most drugs that cause TdP do so via hERG channel blockade, TdP is not necessarily a potential consequence of all drugs blocking the hERG pathway. Milberg et al. 13 compared the TdP induction ability of two hERGblocking drugs, DL-sotalol and amiodarone. While both drugs can increase the QT interval, the former causes transmural DR and triangulation of the action potential by prolonging phase 3, and triggers both EADs and TdP. However, amiodarone does not usually cause DR, EADs, or TdP, and prolonging phase 2 results in a squared-shaped action potential.
While squared-shaped action potentials are considered antiarrhythmic, triangulated action potentials are considered proarrhythmic. 14 Several authors have suggested that DR, attributed to preferential prolongation of the APD of M cells, is a preclinical marker of drug-induced proarrhythmia. 15 However, the existence, location, and clinical contribution of M cells has been a matter of debate. 16 Recent studies have shown that some drugs designated as arrhythmogenic IKr blocker can generate arrhythmias by augmenting I Na-L through the PI3K pathway. 5 For example, while acute exposure of flecainide to adult mouse cardiomyocyte that lack IKr produced no change in ion currents and action potential duration, extended exposure up to 48 hours of the drug generated up to a 15-fold increase in I Na-L and resulted in arrythmogenic EADs. However, not all IKr blockers modulate I Na-L , and this diversity of effects, in return, may contribute to the apparent difference in TdP frequency across culprit drugs. 5 A major implication of this data has to be that relying on an assay to assesses acute block of IKr may not provide a comprehensive assessment of a candidate drug arrhythmogenic potential. Figure 3] ), hypothyroidism, hypothermia, and marked bradycardia, (sinus bradycardia as in Figure 4 , or atrioventricular block).
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Any of these factors can cause acquired LQTS or contribute to the risk of drug-induced LQTS. In addition, there is recent evidence of the high prevalence of QTc interval prolongation in patients with anti-SSA/Ro antibodies, as well as autoimmune and inflammatory diseases. [20] [21] [22] Several recent reports from this laboratory have provided strong evidence for a pathogenic role of autoimmune and inflammatory conditions in the development of QTc prolongation. Anti-Ro antibodies from patients with autoimmune disease were shown to inhibit I Kr by directly cross-reacting with the hERG channel, likely at the pore region where homology between 52Ro antigen and hERG channel was demonstrated. 23 In addition, an animal model of autoimmuneassociated QTc prolongation was established, for the first time, 
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Pharmacogenetics of Acquired Long QT Sydrome
The susceptibility to acquired QT interval prolongation can be influenced by genetic variations. 27 This is supported by the fact that the heritability of QT interval duration in the general population (excluding congenital LQTS patients) is estimated to be around 35%. 28, 29 Further, first-degree relatives of patients with congenital LQTS have a higher risk of drug-induced QT prolongation than nonrelated individuals. 30 In genome-wide association studies (GWAS), a large number of genes associated with QT interval duration has been identified. 31 The gene with the strongest signal related to QT 34 A recent study that compared 188 patients with drug-induced LQTS and more than 1000 patients with congenital LQTS found disease-causing mutations in 28% of patients with druginduced LQTS. 35 Of interest, under basal conditions, the QTc of druginduced LQTS patients (453 ± 39 ms) was significantly longer than that of control subjects (406 ± 26 ms). 35 It is important to consider pharmacogenetics of drug-induced LQTS as related to both pharmacokinetic and pharmacodynamic properties. 27, 34 Pharmacokinetics constitute the effect of the body on the drug, which is usually categorised into effect on absorption, distribution, metabolism, and elimination of the drug. Pharmacokinetic genetic susceptibility is mainly characterised by variation in genes encoding drug-metabolising cytochrome P450 or drug transporter like the P-glycoprotein. However, the pharmacodynamics component of genetic susceptibility is mainly characterised by genes known to be associated with QT prolongation in the general population and genes in which the causal mutations of congenital LQTS are located. 35 Incidence of Drug-induced Long QT Syndrome
The overall incidence of drug-induced LQTS in a given population is difficult to estimate. One study estimated that between 5% and 7% of reports of VT, VF, or SCD were in fact drug-induced LQTS and TdP. 36 European pharmacovigilance centres in Sweden, Germany QT prolongation is one of the most common reasons for drug withdrawal from the market, despite the fact that these drugs may be beneficial for certain patients and not harmful in every patient. 34 Since 1989, 14 clinically important drugs have been removed from the market due to TdP, 38 and development of an unknown number has been stopped, due to concerns that these might pose a risk of causing QT prolongation and TdP. 38 In the 1990s, the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) began requiring routine preclinical and clinical testing to determine whether drugs have the potential to cause QT prolongation. 39 Today, according to the CredibleMeds website, which has become the standard reference for drug-induced TdP, 38 marketed drugs are recognised for their potential to cause TdP and another 72 to cause QT prolongation. 40 In the past decade, hERG channel-mediated cardiac toxicity, manifested as QT interval prolongation, has become a major safety issue in drug development, superseding liver injury as the main cause of drug withdrawals. In vitro electrophysiological testing of the drug's effects on the function of the hERG channel may be cheaper, faster, and potentially more sensitive than other current surrogates for TdP risk, such as in vivo QT prolongation and action potential prolongation in cardiomyocytes. 41 Ethnicity and Gender Differences in Drug-induced Long QT Syndrome
As ethnic differences ultimately reflect genetic variation, it is useful to study ethnicity with regard to susceptibility to drug-induced QT interval prolongation and TdP. However, the role of ethnic differences has not been well established in published studies on drug-induced QT interval prolongation. In 20 QT/QTc studies, only 10% of the total study population was African-American and only 7% was Asian. 42 Nevertheless, the frequency of polymorphisms in genes known from congenital LQTS showed varying distribution among ethnic groups. 43 African-Americans had the highest risk of prolonged QT interval after acute overdose of QT-prolonging drugs, while Hispanics had the lowest risk compared to all other ethnic groups. 44 Females with inherited LQTS demonstrate pronounced gender difference in cardiac repolarisation and arrhythmic risk. Adult women with LQT1 and LQT2 have longer QT intervals, a more pronounced transmural QT dispersion, and a higher risk of TdP and SCD than men. 45, 46 Interestingly, in female patients with LQT2, the arrhythmogenic risk remains elevated after menopause, suggesting that other genderrelated factors besides sex hormones may contribute to gender difference in arrhythmogenesis. 
Electrophysiology & Ablation
Gender is a risk factor for adverse drug reactions. 48, 49 The concept of reduced repolarisation reserve in females compared to males has been used to explain sex differences in arrhythmia risk in acquired LQTS. 50 The reduced repolarisation reserve of the female heart is attributed to lower repolarising K+ currents. This difference was thought to be primarily due to testosterone-mediated increase in I Kr and I K1 resulting in shorter APD and QTc interval in male hearts.
However, in a recent review, the effects of sex hormones go well beyond their modulation of K+ currents. 51 The underlying mechanisms can be summarised as follows: 52 interval. 56 The mechanism of action may be related to suppression of late calcium influx via L-type calcium current and reduction in the amplitude of EADs. 57 If magnesium sulphate fails to suppress TdP, the next step is to increase the heart rate, typically by transvenous pacing. In the interim if necessary, isoproterenol administration could promptly increase the heart rate while waiting for insertion of pacing electrode. Increasing the heart rate is associated with shortening of the QT interval and suppression of TdP. At the same time, the culprit drug should be discontinued and acid-base and electrolytes should be corrected as necessary.
There are novel experimental drugs that can enhance the delayed rectifier conductance 52 or activate the cardiac ATP-sensitive potassium channel, 58 which may have future value for the treatment of acquired LQTS.
Long-term management of acquired LQTS is important. 55, 59 This is especially important for relatives of patients with drug-induced case fatality.
Comprehensive Electrophysiological Mechanisms of Torsade de Pointes
Experimental Models of Long QT Syndrome 
Electrophysiological Mechanisms of the Trigger of Torsade de Pointes in the Long QT Syndrome
There is an almost complete agreement that the initiating one or two beats of TdP are due to EAD-triggered focal activity from the subendocardial Purkinje network. 60, [66] [67] [68] [69] [70] A study by Caref et al. has confirmed beyond reasonable doubt the subendocardial origin of the trigger of TdP.71 71 In this study the canine surrogate model of LQT3 was placed on cardiopulmonary bypass and chemical ablation of the endocardial Purkinje network was obtained using Lugol's iodine following which spontaneous TdP were no longer observed.
However, a properly timed premature stimulus-induced reentrant Veterans Administration (VA) based on the underlying marked DR.
However, the perpetuation of TdP remains controversial and could be attributed to focal activity, reentrant excitation, or a combination of both mechanisms.
The ionic mechanism(s) that underlie the generation of EADs have been widely investigated. The central hypothesis on the generation of EADs suggests that a spontaneous release of calcium from the sarcoplasmic reticulum would temporarily increase cytosolic calcium concentration with a subsequent sudden activation of the sodium-calcium exchanger inward current. This inward current could 're-depolarise' the sarcolemmal membrane to a potential from which sodium or calcium currents become reactivated, triggering an afterdepolarisation. 72 Although this model has been primarily discussed to explain delayed afterdepolarisations, there is also evidence that this mechanism may be the trigger for EADs. 73 This hypothesis is also supported by studies that showed that inhibition of the sodium-calcium exchanger suppresses TdP in the intact heart model of LQTS2 and LQTS3. 74 
Electrophysiological Mechanisms of Perpetuation of Torsade de Pointes
Contrary to the established mechanism of the trigger of TdP, the perpetuation of TdP remains controversial and could be attributed to focal activity, reentrant excitation, or a combination of both mechanisms. 75, 76 Both reentrant and focal activity are assumed to be non-stationary. For reentrant excitation this could be due to a heterogeneity-induced drift of a reentrant circuit, 77 or a meandering reentrant spiral wave 78 ( Figure 1D) . Alternatively, ectopic beats originating from different locations may explain the perpetuation of TdP.
The original description of TdP by Dessertenne attributed the pattern to two variable opposing foci (deux foyers) 7 . In computational modelling as well as experimental observation of the canine chronic AVB model, both multiple competing foci and reentrant excitation could develop depending on heterogeneity of repolarisation in comparison to the surrounding tissue. 75 Large heterogeneities can produce ectopic TdP, while smaller heterogeneities will produce reentrant type TdP. The authors of an experimental study in the same model reported that short-lasting episode of TdP had a focal mechanism while long-lasting episodes were maintained by reentrant excitation. 76 However, the results were criticised because of the controversial definition of focal versus reentrant excitation. One of the problems of sustained fast EAD-induced focal activity is that the short cycle length will be associated with short APD that would suppress further EADs generation unless there is some form of protected islands of prolonged APD with EADs capable of conduction across PMJs to activate the ventricular myocardium. A study that combined computational simulation and experimental observations Delayed After Depolarisation-triggered Activity Contributes to VA in the Long QT Syndrome
The electrophysiological mechanism of VT in LQTS is somewhat more complex than that described earlier. Figure 5A was obtained from one of the classic reviews of cellular mechanisms of cardiac arrhythmias by Hoffman and Rosen. 83 It shows transmembrane AP recording from a canine Purkinje-fiber-superfused with 20-mM caesium chloride (a surrogate experimental model for LQT2). The recording illustrates the classic bradycardia-dependent prolongation of AP duration associated with membrane oscillation on late phase 2/early phase 3 of the repolarisation phase characteristic of EADs. But it also shows that complete repolarisation of the AP is followed by a sub threshold delayed afterdepolarisation (DAD). The latter is simply explained on the basis of increased intracellular Ca2+ associated with the prolonged AP duration triggering a transient inward current. This, almost forgotten, observation strongly suggests that some VT and ectopic beats in LQTS could be secondary to DADs.
Figure 5B shows a corroboration of this observation from the canine surrogate model of LQT3. 84 The top ECG tracing was obtained 10 minutes after infusion of AP-A and shows moderate prolongation of the QT interval and a run of non-sustained monomorphic VT at a rate of 150 bpm. The VT starts with a late coupled beat that is well beyond the end of the QT interval of the preceding sinus beat. Tridimensional mapping of activation showed that the VT arose as a focal discharge (F) from the same subendocardial site. For all practical purposes, the focal discharge could be attributed to DAD-triggered activity.
The bottom ECG tracing was obtained from the same experiment 10 minutes later and shows further prolongation of the QT interval. The ectopic beats labeled F now seem to be coupled to the end of the prolonged QT interval of the preceding sinus beats. The middle of the tracing illustrates a six-beat run of polymorphic VT. Tridimensional mapping shows that the first beat arose from a subendocardial focal site and could be safely attributed to EAD-triggered activity, whereas subsequent beats were due to reentrant excitation in the form of continuously varying scroll waves.
Electrophysiological Mechanisms of Self-terminating versus Non-self-terminating Torsade de Pointes Ventricular Tachyarrhythmia
The majority of TdP episodes terminate spontaneously (self-terminating of TdP VT is due to focal or reentrant activation. 79 Figures 6 and 7
obtained from the canine surrogate model of LQT3 provides one possible electrophysiological mechanism. 84 The lesson gained from this example is that subtle changes in underlying spatial DR and conduction characteristics can result in fractionation of activation wavefronts and VF. It also demonstrates clearly the difficulty in predicting which TdP episodes will be ST of NST.
Future Directions
Although congenital LQTS remains the domain of cardiologists, cardiac electrophysiologists and specialised centres, the far more frequently acquired drug-induced LQTS is the domain of all physicians and other members of healthcare teams who are required to make therapeutic decisions. To support better prescribing of medicines, clinical decision support systems to date have issued alerts that warn of potential harm from a prescribing decision. 85 However, the impact of these systems has been limited. Moving away from the use of alerts to signal prescribing errors, the concept of 'medical autopilots'
has been suggested as a preferred approach. 86 These programs will monitor the electronic medical record and send signals to guide prescribers toward decisions that result in maximum benefit and minimal risk of TdP. 
